<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="page (https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract There have been several episodes of viral" exact="infection" post="evolving into epidemics in recent decades, and severe acute"/>
 <result pre="have resulted in an urgent need to find an effective" exact="treatment" post="modality. Although the category of immunosuppressive drugs usually poses"/>
 <result pre="the category of immunosuppressive drugs usually poses a risk of" exact="infection" post="due to interference of the immune system, some of"/>
 <result pre="tofacitinib, and thalidomide. The inherent antiviral activity could be a" exact="treatment" post="choice for patients with coexisting rheumatological disorders and infections."/>
 <result pre="review article. Lay summary Immunosuppressants often raise the concern of" exact="infection" post="risks, especially for patients with underlying immune disorders. However,"/>
 <result pre="flare up of autoimmune diseases. This review covers DMARDs of" exact="treatment" post="potential for SARS-CoV-2 in part I, and antiviral mechanisms"/>
 <result pre="infections. Certain DMARDs may even be considered as an alternative" exact="treatment" post="for recalcitrant infections. Moreover, the concomitant use of immunosuppressants"/>
 <result pre="discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), DMARDs with" exact="treatment" post="potential are covered in part I. For other viruses,"/>
 <result pre="the efficacy and safety of CQ or HCQ in the" exact="treatment" post="of COVID-19 pneumonia. In the absence of other confirmed"/>
 <result pre="to SARS-CoV-2, both drugs are currently still listed in the" exact="treatment" post="guidelines (Table 1). Table 1. Potential antiviral efficacy of"/>
 <result pre="mitochondrial permeability transition pore opening; RCT, randomized-controlled trial; RT-PCR, real-time" exact="polymerase chain reaction;" post="SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor"/>
 <result pre="to AAK1 and GAK and was identified as a potential" exact="treatment" post="for COVID-19 by artificial intelligence. Intriguingly, other JAK inhibitors"/>
 <result pre="essential enzyme for pyrimidine synthesis, and MMF might control viral" exact="infection" post="by depleting the intracellular pyrimidine pools.28 Thalidomide Thalidomide, a"/>
 <result pre="oral DMARDs have inherent antiviral activity and could be the" exact="treatment" post="of choice for patients with coexisting immune-based diseases and"/>
 <result pre="patients with coexisting immune-based diseases and infections. Especially when the" exact="infection" post="is still in progression, choosing DMARDs with anti-microbial evidence"/>
 <result pre="DMARDs with anti-microbial evidence would bring double benefits for better" exact="infection" post="control without sacrificing underlying disease management. The antimicrobial mechanisms"/>
 <result pre="production of infectious virions RSV (1)â€ƒReduce RSV-mediated cytopathic effects(2)â€ƒPrevent RSV" exact="infection" post="by affecting RSV F protein production or maturation Enterovirus"/>
 <result pre="acid HIV âœ&quot; Chapuis et al.93 âœ&quot; Inhibition of virus" exact="isolation" post="from purified CD4+ T-cell populations.93 âœ&quot; RCT (nâ€‰=â€‰17): combine"/>
 <result pre="with azathioprine developed multiple verrucae and molluscum contagiosum. Due to" exact="treatment" post="resistance, azathioprine was switched to leflunomide (100â€‰mg loading 3â€‰days,"/>
 <result pre="Cytomegalovirus A review article collected 45 transplant recipients with CMV" exact="infection" post="treated by leflunomide. Among them, the plasma CMV viral"/>
 <result pre="healing and viremia clearance.113 Leflunomide was regarded as an add-on" exact="treatment" post="for multi-drug-resistance CMV infection. In vitro anti-CMV properties of"/>
 <result pre="elderly patient with essential thrombocythemia experiencing reactivation of HBV during" exact="treatment" post="with hydroxyurea.73 A retrospective review of children with sickle"/>
 <result pre="easily. The neuroprotection and anti-inflammation effects116,117 brought interest in the" exact="treatment" post="of virus-induced encephalitis such as HIV, Japanese encephalitis virus"/>
 <result pre="efficacy in animal models and in vitro studies for the" exact="treatment" post="of JEV.82,83 A double-blind, RCT allocated 44 pediatric patients"/>
 <result pre="studies.86â€&quot;91 On the contrary, an animal experiment with rabies virus" exact="infection" post="treated by minocycline caused the exacerbation of encephalomyelitis and"/>
 <result pre="further investigation. Zika virus The major concern of Zika virus" exact="infection" post="is that it can transmit from placenta to fetus"/>
 <result pre="fetal mice from microcephaly.54 Therefore, CQ might be a potential" exact="treatment" post="waiting for clinical verification. HCQ had been reported to"/>
 <result pre="I IFN receptors attenuated the efficacy of HCQ in the" exact="treatment" post="of dengue-virus-infected cells.120 On the other hand, a case-control"/>
 <result pre="infections if taking antimalarials.121 Another retrospective study showed significantly lower" exact="infection" post="rate in patients with lupus nephritis and exposure to"/>
 <result pre="survived.94 Middle East respiratory syndrome coronavirus (MERS-CoV) MERS-CoV causes respiratory" exact="infection" post="called MERS or camel flu. Mortality rate is around"/>
 <result pre="Mortality rate is around 33%, and there is no specific" exact="treatment" post="or vaccine for the disease till now. MMF is"/>
 <result pre="the immune system to trigger an antiviral action. Conclusion The" exact="treatment" post="of immune-based diseases has been revolutionized by the introduction"/>
 <result pre="through immunosuppressive and anti-inflammatory effects with the possibility of higher" exact="infection" post="risk. However, many none-biologic DMARDs demonstrate antiviral activities instead."/>
 <result pre="in the face of novel viral infection, such as SARS-CoV-2," exact="screening" post="of existing chemicals, including DMARDs, may prove to be"/>
 <result pre="of combination therapy of antiviral and immunosuppressive drugs for the" exact="treatment" post="of severe acute exacerbation of chronic hepatitis B. J"/>
 <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseases. Pharmacol Res Perspect2017; 5: e00293.28596841"/>
 <result pre="30: 269â€&quot;271.32020029 6GaoJTianZYangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. Biosci Trends2020;"/>
 <result pre="Trends2020; 14: 72â€&quot;73.32074550 7GautretPLagierJCParolaP, et al.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="DOI: 1016/j.ijantimicag.2020.105949. 8ChenJLiuDLiuL, et al.A pilot study of hydroxychloroquine in" exact="treatment" post="of patients with moderate COVID-19. Zhejiang Da Xue Xue"/>
 <result pre="m1849.32409561 13JustinSVenkateshKDe BonoS, et al.Mechanism of baricitinib supports artificial intelligence-predicted" exact="testing" post="in COVID-19 patients. EMBO Mol Med. Epub ahead of"/>
 <result pre="15ChenCQiFShiK, et al.Thalidomide combined with low-dose short-term glucocorticoid in the" exact="treatment" post="of critical Coronvirus Disease 2019. Clin Transl Med. Epub"/>
 <result pre="4 June 2020. DOI: 10.1002/ctm2.35. 16RichardsonPGriffinITuckerC, et al.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet2020; 395: e30â€&quot;e31.32032529 17MehtaPMcAuleyDFBrownM,"/>
 <result pre="395: 1033â€&quot;1034.32192578 18SanchezGAMReinhardtARamseyS, et al.JAK1/2 inhibition with baricitinib in the" exact="treatment" post="of autoinflammatory interferonopathies. J Clin Invest2018; 128: 3041â€&quot;3052.29649002 19FavalliEGBiggioggeroMMaioliG,"/>
 <result pre="434: 658â€&quot;662.15800627 25GoDJParkJKKangEH, et al.Survival benefit associated with early cyclosporine" exact="treatment" post="for dermatomyositis-associated interstitial lung disease. Rheumatol Int2016; 36: 125â€&quot;131.26223808"/>
 <result pre="Medicine. The efficacy and safety of thalidomide in the adjuvant" exact="treatment" post="of moderate new coronavirus (COVID-19) pneumonia. ClinicalTrials.gov identifier: NCT04273529,"/>
 <result pre="32VincentMJBergeronEBenjannetS, et al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J2005; 2: 69.16115318 33SavarinoAGenneroLChenHC, et al.Anti-HIV"/>
 <result pre="zidovudine and hydroxyurea. Biochem Pharmacol2001; 61: 1531â€&quot;1535.11377382 35SperberKLouieMKrausT, et al.Hydroxychloroquine" exact="treatment" post="of patients with human immunodeficiency virus type 1. Clin"/>
 <result pre="44TricouVMinhNNVanTP, et al.A randomized controlled trial of chloroquine for the" exact="treatment" post="of dengue in Vietnamese adults. PLoS Negl Trop Dis2010;"/>
 <result pre="development and challenges. Drug Discov Today2013; 18: 969â€&quot;983.23684571 46BrightonSW.Chloroquine phosphate" exact="treatment" post="of chronic chikungunya arthritis. An open pilot study. S"/>
 <result pre="Med J1984; 66: 217â€&quot;218.6087474 47De LamballerieXBoissonVReynierJC, et al.On chikungunya acute" exact="infection" post="and chloroquine treatment. Vector Borne Zoonotic Dis2008; 8: 837â€&quot;839.18620511"/>
 <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal model. Cell Res2013; 23: 300â€&quot;302.23208422 50BorbaEFSaadCGPasotoSG,"/>
 <result pre="951â€&quot;954.23109461 54LiCZhuXJiX, et al.Chloroquine, a FDA-approved drug, prevents zika virus" exact="infection" post="and its associated congenital microcephaly in mice. EBioMedicine2017; 24:"/>
 <result pre="60InoueKSekiyamaKYamadaM, et al.Combined interferon alpha2b and cyclosporin A in the" exact="treatment" post="of chronic hepatitis C: controlled trial. J Gastroenterol2003; 38:"/>
 <result pre="10: 215â€&quot;217.22308141 73WatanabeNYasudaHAotaY, et al.Reactivation of hepatitis B virus during" exact="treatment" post="with hydroxyurea in an elderly patient with essential thrombocythemia."/>
 <result pre="Biochem Pharmacol2017; 136: 32â€&quot;39.28377277 77HankinsJSPenkertRRLavoieP, et al.Original research: parvovirus B19" exact="infection" post="in children with sickle cell disease in the hydroxyurea"/>
 <result pre="action of minocycline inhibition of human immunodeficiency virus type 1" exact="infection" post="in microglia. J Neurovirol2004; 10: 284â€&quot;292.15385251 79ZinkMCUhrlaubJDeWittJ, et al.Neuroprotective"/>
 <result pre="virus activity of minocycline. JAMA2005; 293: 2003â€&quot;2011.15855434 80SacktorNMiyaharaSDengL, et al.Minocycline" exact="treatment" post="for HIV-associated cognitive impairment: results from a randomized trial."/>
 <result pre="77: 1135â€&quot;1142.21900636 81NakasujjaNMiyaharaSEvansS, et al.Randomized trial of minocycline in the" exact="treatment" post="of HIV-associated cognitive impairment. Neurology2013; 80: 196â€&quot;202.23269596 82MishraMKBasuA.Minocycline neuroprotects,"/>
 <result pre="J Neurochem2008; 105: 1582â€&quot;1595.18208541 83DuttaKKumawatKLNazmiA, et al.Minocycline differentially modulates viral" exact="infection" post="and persistence in an experimental model of Japanese encephalitis."/>
 <result pre="(H5N1 and H7N7) and human (H3N2) viruses and implications for" exact="treatment" post="options. mBio2014; 5: e01102â€&quot;e01113.24496798 90MichaelisMKleinschmidtMCDoerrHW, et al.Minocycline inhibits West"/>
 <result pre="RizzardiGDâ€™AgostinoC, et al.Effects of mycophenolic acid on human immunodeficiency virus" exact="infection" post="in vitro and in vivo. Nat Med2000; 6: 762â€&quot;768.10888924"/>
 <result pre="et al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
 <result pre="experimental immunosuppressive agent leflunomide. Transplantation2001; 71: 170â€&quot;174.11211189 98Henao-MartÃ­nezAFWeinbergAWaldmanWJ, et al.Successful" exact="treatment" post="of acyclovir-resistant herpes simplex virus type 2 proctitis with"/>
 <result pre="HIV-infected man. J Clin Virol2012; 54: 276â€&quot;278.22465339 99RogerMRAnsteadGM.Leflunomide in the" exact="treatment" post="of a pseudotumoral genital herpes simplex virus infection in"/>
 <result pre="in the treatment of a pseudotumoral genital herpes simplex virus" exact="infection" post="in an HIV patient. Case Rep Infect Dis2017; 2017:"/>
 <result pre="6: 69â€&quot;75.16433758 107VerkaikNJHoekRAVan BergeijkH, et al.Leflunomide as part of the" exact="treatment" post="for multidrug-resistant cytomegalovirus disease after lung transplantation: case report"/>
 <result pre="erythematosus. Arthritis Res Ther2012; 14: R155.22734582 119BodewesILAGottenbergJEvan Helden-MeeuwsenCG, et al.Hydroxychloroquine" exact="treatment" post="downregulates systemic interferon activation in primary SjÃ¶grenâ€™s syndrome in"/>
 <result pre="strategies. Lupus2013; 22: 1286â€&quot;1294.24098001 124RubegniPSbanoPDe AloeG, et al.Thalidomide in the" exact="treatment" post="of Kaposiâ€™s sarcoma. Dermatology2007; 215: 240â€&quot;244.17823523"/>
</results>
